Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMVBK6)

• Drug Name: JP1302 Drug Info
• Synonyms: N-(4-(4-Methyl-1-piperazinyl)phenyl)-9-acridinamine; GNF-PF-3427; TCMDC-123912; BRN 5117597; 80259-18-3; MMV006172; JP 1302; N-[4-(4-methylpiperazin-1-yl)phenyl]acridin-9-amine; CHEMBL106525; QZKGUNQLVFEEBA-UHFFFAOYSA-N; 9-Acridinamine, N-(4-(4-methyl-1-piperazinyl)phenyl)-; Acridin-9-yl-[4-(4-methyl-piperazin-1-yl)-phenyl]-amine; N-(4-(4-methylpiperazin-1-yl)phenyl)acridin-9-amine; N-[4-(4-Methyl-1-piperazinyl)phenyl]-9-acridinamine; 9-Acridinamine, N-[4-(4-methyl-1-piperazinyl)phenyl]-; JP-1302; JP-1302

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 540335
  CAS Number: CAS 80259-18-3
  TTD Drug ID: DMMVBK6

Molecule-Related Drug Atlas

Drug(s) Targeting Adrenergic receptor alpha-2C (ADRA2C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MOXONIDINE	DMGFB0E	Alcohol dependence	6C40.2	Approved	[4]
Dihydroergocristine	DM5SQ1G	Alcohol dependence	6C40.2	Approved	[5]
Brimonidine	DMQLT4N	Ocular hypertension	9C61.01	Approved	[6]
Amosulalol	DML8QSZ	Hypertension	BA00-BA04	Approved	[7]
Amezinium	DM6I2WQ	Hypotension	BA20-BA21	Approved	[8]
Propylhexedrine	DMTBW2O	Obesity	5B81	Approved	[9]
Tetrahydrozoline	DMT57WC	Ocular disease	1F00.1Z	Approved	[10]
Rilmenidine	DM13PQW	Hypertension	BA00-BA04	Approved	[11]
Xylometazoline	DMKV32D	Allergic rhinitis	CA08.0	Phase 4	[12]
TNX-102	DMO1234	Fibromyalgia	MG30.01	Phase 3	[13]

Drug(s) Targeting Adrenergic receptor alpha-2A (ADRA2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lofexidine	DM1WXA6	Heroin and opiate withdrawal	6C43	Approved	[14]
MOXONIDINE	DMGFB0E	Alcohol dependence	6C40.2	Approved	[4]
Connexyn	DMF29Q5	Attention deficit hyperactivity disorder	6A05.Z	Approved	[15]
Guanfacine	DMPN5IH	Attention deficit hyperactivity disorder	6A05.Z	Phase 4	[16]
A295	DM55GO2	Aggressive cancer	2A00-2F9Z	IND submitted	[17]
MEDETOMIDINE	DMX9Y7V	Pain	MG30-MG3Z	Phase 2	[18]
DSP-1200	DM4WSHG	Depression	6A70-6A7Z	Phase 1	[19]
MAZAPERTINE	DMRHYAU	N. A.	N. A.	Discontinued in Phase 2	[20]
NMI-870	DMU596F	Sexual dysfunction	HA00-HA01	Discontinued in Phase 2	[21]
SNAP-5089	DMROJEN	Heart arrhythmia	BC65	Terminated	[22]

Drug(s) Targeting Adrenergic receptor alpha-2B (ADRA2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MOXONIDINE	DMGFB0E	Alcohol dependence	6C40.2	Approved	[4]
MEDETOMIDINE	DMX9Y7V	Pain	MG30-MG3Z	Phase 2	[18]
AGN-199981	DMP5Y1A	Neuropathic pain	8E43.0	Phase 2	[23]
INDORAMIN	DMNSJFD	Hypertension	BA00-BA04	Withdrawn from market	[24]
MAZAPERTINE	DMRHYAU	N. A.	N. A.	Discontinued in Phase 2	[20]
SNAP-5089	DMROJEN	Heart arrhythmia	BC65	Terminated	[22]
A-80426	DMBC3DG	N. A.	N. A.	Terminated	[25]
WB-4101	DMQU8B1	N. A.	N. A.	Terminated	[26]
SK&F-104078	DMRADBU	N. A.	N. A.	Terminated	[24]
(+/-)-nantenine	DM0L3GE	Discovery agent	N.A.	Investigative	[27]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor alpha-2A (ADRA2A)	TTWG9A4	ADA2A_HUMAN	Inhibitor	[2]
Adrenergic receptor alpha-2B (ADRA2B)	TTWM4TY	ADA2B_HUMAN	Inhibitor	[2]
Adrenergic receptor alpha-2C (ADRA2C)	TT2NUT5	ADA2C_HUMAN	Antagonist	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3930).
• [2] Structure-activity relationship of quinoline derivatives as potent and selective alpha(2C)-adrenoceptor antagonists. J Med Chem. 2006 Oct 19;49(21):6351-63.
• [3] Pharmacological characterization and CNS effects of a novel highly selective alpha2C-adrenoceptor antagonist JP-1302. Br J Pharmacol. 2007 Feb;150(4):391-402.
• [4] Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5.
• [5] Effect of dihydroergocristine on blood pressure and activity at peripheral alpha-adrenoceptors in pithed rats. Eur J Pharmacol. 1984 Jan 13;97(1-2):21-7.
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 520).
• [7] Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5.
• [8] Pharmacology of amezinium, a novel antihypotensive drug. III. Studies on the mechanism of action. Arzneimittelforschung. 1981;31(9a):1558-65.
• [9] Airway compromise and delayed death following attempted central vein injection of propylhexedrine. J Emerg Med. 1994 Nov-Dec;12(6):795-7.
• [10] Prolonged cardiovascular effects after unintentional ingestion of tetrahydrozoline. Clin Toxicol (Phila). 2008 Feb;46(2):171-2.
• [11] Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha 2 receptors. Curr Eye Res. 1996 Sep;15(9):943-50.
• [12] Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39.
• [13] Clinical pipeline report, company report or official report of Tonix Pharmaceuticals.
• [14] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [15] alpha2A-adrenergic receptors heterosynaptically regulate glutamatergic transmission in the bed nucleus of the stria terminalis. Neuroscience. 2009 Sep 29;163(1):339-51.
• [16] Scientific rationale for the use of alpha2A-adrenoceptor agonists in treating neuroinflammatory cognitive disorders. Mol Psychiatry. 2023 Apr 7:1-13.
• [17] Clinical pipeline report, company report or official report of Klus Pharma
• [18] A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
• [19] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [20] A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
• [21] Female Sexual Dysfunction: Therapeutic Options and Experimental Challenges. Cardiovasc Hematol Agents Med Chem. 2009 October; 7(4): 260-269.
• [22] Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8.
• [23] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [24] Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44.
• [25] Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71.
• [26] alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401.
• [27] Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.